Lactate Dehydrogenase A is a potential prognostic marker in clear cell renal cell carcinoma

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Girgis, Hala ^a,b   Masui, Olena ^c   White, Nicole M A ^a,b,d   Scorilas, Andreas ^e   Rotondo, Fabio ^a,b   Seivwright, Annetta ^a,b   Gabril, Manal ^f   Filter, Emily R ^f   Girgis, Andrew H A ^a,b   Bjarnason, Georg A ^g   Jewett, Michael A S ^h   Evans, Andrew ^d,i   Al Haddad, Sahar ^a,b,d   Siu, KW M ^c   Yousef, George M ^a,b,d  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c YORK UNIVERSITY   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF ATHENS   (Greece)

^f UNIVERSITY OF WESTERN ONTARIO   (Canada)

^g DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^h University Health Network   (Canada)

ⁱ UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Lactate dehydrogenase A; Metastasis; Pathology; Personalized medicine; Prognosis; Proteomics; Renal cell carcinoma; Tumor markers

Indexed keywords

LACTATE DEHYDROGENASE; LACTATE DEHYDROGENASE ISOENZYME 5; MESSENGER RNA; UNCLASSIFIED DRUG; ISOENZYME; LACTATE DEHYDROGENASE 5; TUMOR MARKER;

ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FEMALE; GENETIC DATABASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN EXPRESSION; CARCINOMA, RENAL CELL; GENE EXPRESSION REGULATION; GENETICS; KIDNEY NEOPLASMS; METABOLISM; MORTALITY; PATHOLOGY; PERSONALIZED MEDICINE; PROGNOSIS; SURVIVAL; TUMOR VOLUME;

CARCINOMA, RENAL CELL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDIVIDUALIZED MEDICINE; ISOENZYMES; KIDNEY NEOPLASMS; L-LACTATE DEHYDROGENASE; MALE; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; RNA, MESSENGER; SURVIVAL ANALYSIS; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84900837970     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-101     Document Type: Article

References (51)

1. Simard EP, Ward EM, Siegel R, Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin 2012, 62:118-124.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29. 10.3322/caac.20138, 22237781.
3. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 2003, 27:612-624. 10.1097/00000478-200305000-00005, 12717246.
4. Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, Mackenzie M, Wood L, Donsko F, Tan MH, Rha SY, Agarwal N, Kollmannsberger C, Rini BI, Choueiri TK. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol 2013, 14:141-148. 10.1016/S1470-2045(12)70559-4, 23312463.
5. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009, 27:5794-5799. 10.1200/JCO.2008.21.4809, 19826129.
6. Pasic MD, Samaan S, Yousef GM. Genomic medicine: new frontiers and new challenges. Clin Chem 2013, 59:158-167. 10.1373/clinchem.2012.184622, 23284016.
7. White NM, Yousef GM. Translating molecular signatures of renal cell carcinoma into clinical practice. J Urol 2011, 186:9-11. 10.1016/j.juro.2011.04.003, 21571339.
8. Faragalla H, Youssef YM, Scorilas A, Khalil B, White NM, Mejia-Guerrero S, Khella H, Jewett MA, Evans A, Lichner Z, Bjarnason G, Sugar L, Attalah MI, Yousef GM. The clinical utility of miR-21 as a diagnostic and prognostic marker for renal cell carcinoma. J Mol Diagn 2012, 14:385-392. 10.1016/j.jmoldx.2012.02.003, 22580180.
9. Khella HW, White NM, Faragalla H, Gabril M, Boazak M, Dorian D, Khalil B, Antonios H, Bao TT, Pasic MD, Honey RJ, Stewart R, Pace KT, Bjarnason GA, Jewett MA, Yousef GM. Exploring the role of miRNAs in renal cell carcinoma progression and metastasis through bioinformatic and experimental analyses. Tumour Biol 2012, 33:131-140. 10.1007/s13277-011-0255-5, 22086373.
10. Tan PH, Cheng L, Rioux-Leclercq N, Merino MJ, Netto G, Reuter VE, Shen SS, Grignon DJ, Montironi R, Egevad L, Srigley JR, Delahunt B, Moch H. Renal tumors: diagnostic and prognostic biomarkers. Am J Surg Pathol 2013, 37:1518-1531. 10.1097/PAS.0b013e318299f12e, 24025522.
11. Zhang BY, Thompson RH, Lohse CM, Dronca RS, Cheville JC, Kwon ED, Leibovich BC. Carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long-term follow-up. BJU Int 2013, 111:1046-1053. 10.1111/bju.12075, 23551810.
12. Yun J, Johnson JL, Hanigan CL, Locasale JW. Interactions between epigenetics and metabolism in cancers. Front Oncol 2012, 2:163. 3498627, 23162793.
13. Ashrafian H, O'Flaherty L, Adam J, Steeples V, Chung YL, East P, Vanharanta S, Lehtonen H, Nye E, Hatipoglu E, Miranda M, Howarth K, Shukla D, Troy H, Griffiths J, Spencer-Dene B, Yusuf M, Volpi E, Maxwell PH, Stamp G, Poulsom R, Pugh CW, Costa B, Bardella C, Di Renzo MF, Kotlikoff MI, Launonen V, Aaltonen L, El-Bahrawy M, Tomlinson I, et al. Expression profiling in progressive stages of fumarate-hydratase deficiency: the contribution of metabolic changes to tumorigenesis. Cancer Res 2010, 70:9153-9165. 10.1158/0008-5472.CAN-10-1949, 20978192.
14. Gordan JD, Thompson CB, Simon MC. HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell 2007, 12:108-113. 10.1016/j.ccr.2007.07.006, 3215289, 17692803.
15. Seyfried TN, Shelton LM. Cancer as a metabolic disease. Nutr Metab (Lond) 2010, 7:7. 10.1186/1743-7075-7-7, 2845135, 20181022.
16. Amann T, Maegdefrau U, Hartmann A, Agaimy A, Marienhagen J, Weiss TS, Stoeltzing O, Warnecke C, Scholmerich J, Oefner PJ, Kreutz M, Bosserhoff AK, Hellerbrand C. GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis. Am J Pathol 2009, 174:1544-1552. 10.2353/ajpath.2009.080596, 2671384, 19286567.
17. Yao F, Zhao T, Zhong C, Zhu J, Zhao H. LDHA is necessary for the tumorigenicity of esophageal squamous cell carcinoma. Tumour Biol 2013, 34:25-31. 10.1007/s13277-012-0506-0, 22961700.
18. Sheng SL, Liu JJ, Dai YH, Sun XG, Xiong XP, Huang G. Knockdown of lactate dehydrogenase A suppresses tumor growth and metastasis of human hepatocellular carcinoma. FEBS J 2012, 279:3898-3910. 10.1111/j.1742-4658.2012.08748.x, 22897481.
19. Le A, Cooper CR, Gouw AM, Dinavahi R, Maitra A, Deck LM, Royer RE, Vander Jagt DL, Semenza GL, Dang CV. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci U S A 2010, 107:2037-2042. 10.1073/pnas.0914433107, 2836706, 20133848.
20. Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 2006, 9:425-434. 10.1016/j.ccr.2006.04.023, 16766262.
21. Masui O, White NM, DeSouza LV, Krakovska O, Matta A, Metias S, Khalil B, Romaschin AD, Honey RJ, Stewart R, Pace K, Bjarnason GA, Siu KW, Yousef GM. Quantitative proteomic analysis in metastatic renal cell carcinoma reveals a unique set of proteins with potential prognostic significance. Mol Cell Proteomics 2013, 12:132-144. 10.1074/mcp.M112.020701, 3536894, 23082029.
22. White NM, Newsted DW, Masui O, Romaschin AD, Siu KW, Yousef GM. Identification and validation of dysregulated metabolic pathways in metastatic renal cell carcinoma. Tumour Biol 2013, 35:1833-46.
23. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982, 6:655-663. 10.1097/00000478-198210000-00007, 7180965.
24. Pavlovich CP, Schmidt LS. Searching for the hereditary causes of renal-cell carcinoma. Nat Rev Cancer 2004, 4:381-393. 10.1038/nrc1364, 15122209.
25. Singer K, Kastenberger M, Gottfried E, Hammerschmied CG, Buttner M, Aigner M, Seliger B, Walter B, Schlosser H, Hartmann A, Andreesen R, Mackensen A, Kreutz M. Warburg phenotype in renal cell carcinoma: high expression of glucose-transporter 1 (GLUT-1) correlates with low CD8(+) T-cell infiltration in the tumor. Int J Cancer 2011, 128:2085-2095. 10.1002/ijc.25543, 20607826.
26. Siu KW, DeSouza LV, Scorilas A, Romaschin AD, Honey RJ, Stewart R, Pace K, Youssef Y, Chow TF, Yousef GM. Differential protein expressions in renal cell carcinoma: new biomarker discovery by mass spectrometry. J Proteome Res 2009, 8:3797-3807. 10.1021/pr800389e, 19610612.
27. Girgis AH, Iakovlev VV, Beheshti B, Bayani J, Squire JA, Bui A, Mankaruos M, Youssef Y, Khalil B, Khella H, Pasic M, Yousef GM. Multilevel whole-genome analysis reveals candidate biomarkers in clear cell renal cell carcinoma. Cancer Res 2012, 72:5273-5284. 10.1158/0008-5472.CAN-12-0656, 22926558.
28. White NM, Bao TT, Grigull J, Youssef YM, Girgis A, Diamandis M, Fatoohi E, Metias M, Honey RJ, Stewart R, Pace KT, Bjarnason GA, Yousef GM. miRNA profiling for clear cell renal cell carcinoma: biomarker discovery and identification of potential controls and consequences of miRNA dysregulation. J Urol 2011, 186:1077-1083. 10.1016/j.juro.2011.04.110, 21784468.
29. Chow TF, Youssef YM, Lianidou E, Romaschin AD, Honey RJ, Stewart R, Pace KT, Yousef GM. Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis. Clin Biochem 2010, 43:150-158. 10.1016/j.clinbiochem.2009.07.020, 19646430.
30. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis?. Nat Rev Cancer 2004, 4:891-899. 10.1038/nrc1478, 15516961.
31. Garber K. Energy deregulation: licensing tumors to grow. Science 2006, 312:1158-1159. 10.1126/science.312.5777.1158, 16728625.
32. Garland J. Energy management - a critical role in cancer induction?. Crit Rev Oncol Hematol 2013, 88:198-217. 10.1016/j.critrevonc.2013.04.001, 23731619.
33. Yang Y, Valera VA, Padilla-Nash HM, Sourbier C, Vocke CD, Vira MA, Abu-Asab MS, Bratslavsky G, Tsokos M, Merino MJ, Pinto PA, Srinivasan R, Ried T, Neckers L, Linehan WM. UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer. Cancer Genet Cytogenet 2010, 196:45-55. 10.1016/j.cancergencyto.2009.08.018, 2827193, 19963135.
34. Romaschin AD, Youssef Y, Chow TF, Siu KW, DeSouza LV, Honey RJ, Stewart R, Pace KT, Yousef GM. Exploring the pathogenesis of renal cell carcinoma: pathway and bioinformatics analysis of dysregulated genes and proteins. Biol Chem 2009, 390:125-135.
35. Linehan WM, Rouault TA. Molecular pathways: Fumarate hydratase-deficient kidney cancer-targeting the Warburg effect in cancer. Clin Cancer Res 2013, 19:3345-3352. 10.1158/1078-0432.CCR-13-0304, 23633457.
36. Serganova I, Rizwan A, Ni X, Thakur SB, Vider J, Russell J, Blasberg R, Koutcher JA. Metabolic imaging: a link between lactate dehydrogenase A, lactate, and tumor phenotype. Clin Cancer Res 2011, 17:6250-6261. 10.1158/1078-0432.CCR-11-0397, 21844011.
37. Xie H, Valera VA, Merino MJ, Amato AM, Signoretti S, Linehan WM, Sukhatme VP, Seth P. LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Mol Cancer Ther 2009, 8:626-635. 10.1158/1535-7163.MCT-08-1049, 2671637, 19276158.
38. Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 2006, 25:4633-4646. 10.1038/sj.onc.1209597, 16892078.
39. Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN, Keatin MJ, Huang P. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 2005, 65:613-621.
40. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999, 17:2530-2540.
41. Mekhail TM, Abou-Jawde RM, Boumerhi G, Malhi S, Wood L, Elson P, Bukowski R. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005, 23:832-841. 10.1200/JCO.2005.05.179, 15681528.
42. Nieder C, Marienhagen K, Dalhaug A, Norum J. Towards improved prognostic scores predicting survival in patients with brain metastases: a pilot study of serum lactate dehydrogenase levels. Scientific World Journal 2012, 2012:609323. 3345873, 22593701.
43. Cifola I, Spinelli R, Beltrame L, Peano C, Fasoli E, Ferrero S, Bosari S, Signorini S, Rocc F, Pereg R, Proserpio V, Raimondo F, Mocarelli P, Battaglia C. Genome-wide screening of copy number alterations and LOH events in renal cell carcinomas and integration with gene expression profile. Mol Cancer 2008, 7:6. 10.1186/1476-4598-7-6, 2253555, 18194544.
44. Sanjmyatav J, Junker K, Matthes S, Muehr M, Sava D, Sternal M, Wessendorf S, Kreuz M, Gajda M, Wunderlich H, Schwaenen C. Identification of genomic alterations associated with metastasis and cancer specific survival in clear cell renal cell carcinoma. J Urol 2011, 186:2078-2083. 10.1016/j.juro.2011.06.050, 21944119.
45. Metias SM, Lianidou E, Yousef GM. MicroRNAs in clinical oncology: at the crossroads between promises and problems. J Clin Pathol 2009, 62:771-776. 10.1136/jcp.2009.064717, 19734473.
46. Wuttig D, Zastrow S, Fussel S, Toma MI, Meinhardt M, Kalman K, Junker K, Sanjmyatav J, Boll K, Hackermuller J, Rolle A, Grimm MO, Wirth MP. CD31, EDNRB and TSPAN7 are promising prognostic markers in clear-cell renal cell carcinoma revealed by genome-wide expression analyses of primary tumors and metastases. Int J Cancer 2012, 131:E693-E704. 10.1002/ijc.27419, 22213152.
47. Stillebroer AB, Mulders PF, Boerman OC, Oyen WJ, Oosterwijk E. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Eur Urol 2010, 58:75-83. 10.1016/j.eururo.2010.03.015, 20359812.
48. Kroeze SG, Vermaat JS, van Brussel A, van Melick HH, Voest EE, Jonges TG, van Diest PJ, Hinrichs J, Bosch JL, Jans JJ. Expression of nuclear FIH independently predicts overall survival of clear cell renal cell carcinoma patients. Eur J Cancer 2010, 46:3375-3382. 10.1016/j.ejca.2010.07.018, 20709525.
49. Gossage L, Eisen T. Alterations in VHL as potential biomarkers in renal-cell carcinoma. Nat Rev Clin Oncol 2010, 7:277-288. 10.1038/nrclinonc.2010.42, 20368728.
50. Iakovlev VV, Gabril M, Dubinski W, Scorilas A, Youssef YM, Faragalla H, Kovacs K, Rotondo F, Metias S, Arsaniousn A, Plotki A, Girgis AH, Streutker C, Yousef GM. Microvascular density as an independent predictor of clinical outcome in renal cell carcinoma: an automated image analysis study. Lab Invest 2012, 92:46-56. 10.1038/labinvest.2011.153, 22042086.
51. Lichner Z, Scorilas A, White NM, Girgis AH, Rotstein L, Wiegand KC, Latif A, Chow C, Huntsman D, Yousef GM. The chromatin remodeling gene ARID1A is a new prognostic marker in clear cell renal cell carcinoma. Am J Pathol 2013, 182:1163-1170. 10.1016/j.ajpath.2013.01.007, 23416164.